Source: Fox News
Summary
The Centers for Disease Control and Prevention (CDC) and the White House Office of National Drug Control Policy (ONDCP) have issued a health advisory about the presence of medetomidine, a veterinary sedative, in the illegal fentanyl supply. Medetomidine, also known as “rhino tranq,” can cause severe, prolonged sedation and life-threatening withdrawal symptoms. The advisory is based on surveillance data, including forensic drug testing and overdose investigations, which show a significant increase in medetomidine detection in fentanyl samples. The drug has been detected in at least 18 states and Washington, D.C. Naloxone, commonly used to reverse opioid overdoses, does not counteract medetomidine.
Our Reading
The advice sounds familiar.
Medetomidine’s presence in the fentanyl supply marks another phase in the evolving illicit opioid landscape. The CDC’s surveillance data reveals a more than 3,000% increase in medetomidine detection in fentanyl samples between 2023 and 2025. The veterinary sedative’s co-occurrence with fentanyl complicates overdose presentation and withdrawal management, increasing clinical acuity and unpredictability. Naloxone’s ineffectiveness against medetomidine underscores the need for careful assessment and coordination with toxicology, emergency medicine, and public health partners. As the drug supply continues to evolve, addiction care must adapt to address the complex needs of individuals affected.
The situation feels like another example of how the illicit opioid supply can strain traditional frameworks and demand greater clinical vigilance.
Author: Evan Null
